Biocon’s launch of the world’s first bio-similar of Trastuzumab, a critical breast cancer drug, is unlikely to benefit patients in a big way if the company sticks to the prices it has indicated, claimed health activists on Monday. They allege that Roche, which retails the drug at . 75,000 for 440 mg vial, sells it at a discount to its long-term patients through many of its dealers for . 55,000-57,000. Biocon’s retail price of . 56,000 per 440 mg vial doesn’t make the drug much cheaper.
Source: The Times of India Read more
0 Comments
The Drug Controller General of India (DCGI) has released draft guidelines that make it mandatory for clinical research organisations to conduct an audiovisual recording of the trial patients informing them about each and every risk involved while undergoing the trial.
Source: The Times of India Read more The Centre will soon include Third Line therapy for persons living with HIV in the government’s Anti-Retroviral Treatment programme.
Preliminary work has begun in this regard and the process is expected to be completed in eight to 10 months, Lov Verma, Secretary, Department of AIDS Control, Ministry of Health and Family Welfare, said on Saturday. Source: The Hindu Read more The Union Cabinet has sanctioned the setting up of 71 stand-alone cancer care institutes throughout India at a cost of Rs.6,650 crores in order to tackle the problem posed by the increasing incidence of cancer and the increasing deaths due to cancer in the country, Union Minister for Health and Family Welfare Ghulam Nabi Azad has said.
Source: The Hindu Read more |
Back >>>News on Other Repro Health
This is a collection of news clippings from differnt newspapers on other reproductive health issues Archives
February 2014
Categories |